<DOC>
	<DOCNO>NCT00002399</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness SCH 56592 fluconazole treatment OPC ( fungal infection throat ) HIV-positive patient .</brief_summary>
	<brief_title>A Comparison SCH 56592 Fluconazole Treatment Oropharyngeal Candidiasis ( OPC ) HIV-Positive Patients</brief_title>
	<detailed_description>This randomize , multicenter , double-blind study consist 5 arm ( 4 dose level SCH 56592 v fluconazole ) treatment oropharyngeal candidiasis ( OPC ) HIV-positive patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Oral</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV seropositivity ( Western blot approve confirmatory test ) prior enrollment . Pseudomembranous oropharyngeal candidiasis . Fungal stain KOH consistent Candida specie , confirm positive mycologic culture . Ability swallow study medication . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Medical condition require use prohibit drug . Primary HIV seroconversionrelated mucosal candidiasis . Systemic candidiasis . All form OPC pseudomembranous ( unless accompany pseudomembranous OPC ) . Documented suspected fungal esophagitis patient symptoms esophagitis . EKG prolong QTc interval clinicallysignificant abnormality . Concurrent Medication : Excluded : Systemic antifungal ( IV oral ) . Topical oral antifungal , e.g. , Nystatin , Mycelex , etc . Medications know interact azoles may lead lifethreatening side effect : terfenadine , astemizole , cisapride , ebastine , triazolam , midazolam . Medications know low serum concentration/efficacy azole antifungal : rifampin , carbamazepine , phenytoin , rifabutin , barbiturate , isoniazid , H2 blocker . Cytokines ( except erythropoietin ) , interferon , lymphocyte replacement therapy unless patient already take agent least 30 day prior enrollment . Protease inhibitor , start first time , 30 day prior study enrollment . Cytotoxic therapy cancer . Oral intravenous corticosteroid supraphysiologic dos ( prednisone 10 mg/day great ; hydrocortisone 40 mg/day great ; dexamethasone 2 mg/day great . Patients follow prior condition exclude : Prior enrollment study . Less 3 month life expectancy . History hypersensitivity azole antifungal . History fail therapy fluconazole 100 mg/day 2 week last 3 month . Prior Medication : Excluded ( washouts medication ) : Systemic antifungal ( IV , oral ) within 14 day prior enrollment . Topical oral antifungal within 1 day prior enrollment . Oral intravenous corticosteroid supraphysiologic dos within 10 day prior enrollment . Astemizole within 10 day prior enrollment . Drugs know low serum concentration/efficacy azole antifungal within 30 day prior enrollment . Investigational drug ( unlicensed new chemical entity ) use within 30 day prior enrollment . Current known drug abuse , opinion lead investigator , would interfere subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 1999</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Triazoles</keyword>
</DOC>